Lv2
140 积分 2025-08-20 加入
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
22天前
已完结
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
25天前
已完结
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
2个月前
已完结
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
4个月前
已完结
Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity
4个月前
已完结
Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity
4个月前
已完结
Chinese SLE Treatment and Research Group (CSTAR) Registry 2009-2019: Major Clinical Characteristics of Chinese Patients with Systemic Lupus Erythematosus
5个月前
已完结
EULAR recommendations for the treatment of systemic sclerosis: 2023 update
5个月前
已完结
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
5个月前
已完结
皖公网安备34019202002308
